2022
Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States
Coburn SB, Humes E, Lang R, Stewart C, Hogan BC, Gebo KA, Napravnik S, Edwards JK, Browne LE, Park LS, Justice AC, Gordon KS, Horberg MA, Certa JM, Watson E, Jefferson CR, Silverberg MJ, Skarbinski J, Leyden WA, Williams CF, Althoff KN. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States. JAMA Network Open 2022, 5: e2215934. PMID: 35671054, PMCID: PMC9175076, DOI: 10.1001/jamanetworkopen.2022.15934.Peer-Reviewed Original ResearchConceptsBreakthrough infectionsFull vaccinationAdditional doseSARS-CoV-2 infection riskBreakthrough COVID-19 infectionsCOVID-19 breakthrough infectionsHIV viral load suppressionInfection riskSARS-CoV-2 infectionBreakthrough infection riskHigher CD4 countsViral load suppressionHIV viral loadAdditional vaccine dosesCOVID-19 vaccinationCOVID-19 infectionIntegrated health systemNon-Hispanic blacksCOVID-19 vaccineSARS-CoV-2Non-Hispanic whitesExpansion of RecommendationsCOVID-19 diagnosisAdvanced diseaseCD4 count
2016
The impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy
Edelman E, Gordon K, Tate J, Becker W, Bryant K, Crothers K, Gaither, Gibert C, Gordon A, Marshall B, Rodriguez‐Barradas M, Samet J, Skanderson M, Justice A, Fiellin D. The impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy. HIV Medicine 2016, 17: 728-739. PMID: 27186715, PMCID: PMC5053822, DOI: 10.1111/hiv.12377.Peer-Reviewed Original ResearchConceptsCD4 cell countBaseline CD4 cell countCell countPrescribed opioidsImmunosuppressive propertiesVeterans Aging Cohort Study (VACS) dataCD4 cell count recoveryAntiretroviral therapy responseCell count recoveryShort-term opioidsViral load suppressionCohort study dataOverall disease severityYear of initiationPrimary independent variableOpioid durationAntiretroviral therapyCount recoveryComorbid conditionsPharmacy dataOpioid propertiesTherapy responseOpioidsPatientsHIV
2015
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy
Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, Rimland D, Rodriguez-Barradas MC, Jacobson LP. Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 493-498. PMID: 25886923, PMCID: PMC4482798, DOI: 10.1097/qai.0000000000000643.Peer-Reviewed Original ResearchConceptsHIV RNA suppressionOdds of suppressionActive antiretroviral therapyRNA suppressionHAART regimenAntiretroviral therapyVeterans Aging Cohort Study Virtual CohortHighly Active Antiretroviral TherapyFirst HAART regimenProtease inhibitor usersRepeated-measures logistic regressionVeterans' Affairs pharmacyViral load suppressionHAART usersNew HAARTRegimen typeInhibitor usersHIV infectionNonnucleoside reverseLow adherenceAdherence levelsPerfect adherenceVirtual cohortLogistic regressionDuration of timeNumber of Drinks to “Feel a Buzz” by HIV Status and Viral Load in Men
McGinnis KA, Fiellin DA, Tate JP, Cook RL, Braithwaite RS, Bryant KJ, Edelman EJ, Gordon AJ, Kraemer KL, Maisto SA, Justice AC, The Veterans Aging Cohort Study. Number of Drinks to “Feel a Buzz” by HIV Status and Viral Load in Men. AIDS And Behavior 2015, 20: 504-511. PMID: 26936030, PMCID: PMC4780364, DOI: 10.1007/s10461-015-1053-7.Peer-Reviewed Original ResearchConceptsUninfected menNumber of drinksViral load suppressionMean numberImpact of HIVBlood alcohol concentrationEffects of alcoholAntiretroviral initiationDetectable VLCohort studyVL suppressionHIV statusMultivariable analysisViral loadLower mean numberHIVCurrent drinkingMenDrinksAlcohol concentrationSuppression
2013
A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care
Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R. A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care. AIDS And Behavior 2013, 17: 2293-2300. PMID: 23404097, PMCID: PMC3742414, DOI: 10.1007/s10461-013-0416-1.Peer-Reviewed Original ResearchConceptsViral load suppressionFeasibility outcomesPatient acceptabilityPatient comprehensionPlasma HIV RNADetectable viral loadViral load testsSingle-site studyEligible patientsHIV careHIV RNAART adherenceViral loadHIV transmissionOwn controlPatientsPatient workflowFinancial incentivesOutcomesCareDownstream costsIncentive sizeBiological outcomesAcceptabilityClinic